Artificial Blood and Plasma: Global Markets to 2027

Summary Table: Global Market for Artificial Blood, Through 2028
Table 1: Historical Events Related to Blood Transfusion, 1628-2022
Table 2: Potential Benefits and Application Areas of Artificial Blood
Table 3: Average Number of Blood Units Required During Particular Medical Conditions
Table 4: The Challenges Associated with the Development of Artificial Blood
Table 5: Common Challenges to the Blood Transfusion Continuum in LMICs.
Table 6: Sources of Hemoglobin Molecules Used to Prepare Free Hemoglobin Solutions
Table 7: Pros and Cons of Artificial Blood Developed from Human Blood
Table 8: Pros and Cons of Artificial Blood Developed from Animal Blood
Table 9: Pros and Cons of Artificial Blood Developed from Recombinant Blood
Table 10: Summary of Acellular Hb-Based Oxygen Carriers
Table 11: Examples of Hemoglobin-based Oxygen Carrier Products and Approval Status
Table 12: Potential Clinical Applications of Oxygen Carriers
Table 13: Composition of PFC Emulsion-Based Artificial Blood Products
Table 14: First Generation Perfluorocarbon Emulsions Used in Medicine and Biology
Table 15: Comparative Study of Second-Generation PFCs
Table 16: PFC Emulsion Products and Current Status
Table 17: Comparative Study Between RBCs and HBOCs
Table 18: HBOC Solutions Transfusion: Side Effects and Possible Causes
Table 19: Examples of HBOC Products Developed, by Various Companies
Table 20: Global Market for Artificial Blood, Through 2028
Table 21: Current Cell Sources and Strategies for Ex-vivo RBC Generation
Table 22: List of Discontinued Blood Substitutes
Table 23: Hemopure: Raw Material and Method Overview
Table 24: Hemopure: Product Characteristics
Table 25: Hemopure: Advantages and Disadvantages
Table 26: Summary of Clinical Trials of Hemopure (HBOC-201), 2023
Table 27: HemO2life: Raw Material and Method
Table 28: HemO2life: Advantages and Disadvantages
Table 29: HemO2life: Product
Table 30: Ex vivo, In vivo and Clinical Studies involving HemO2life (M101) Use
Table 31: Hemotech: Raw Material and Method Overview
Table 32: HemoTech: Advantages and Disadvantages
Table 33: NanO2 (DDFPe): Raw Material and Method Overview
Table 34: NanO2 (DDFPe): Advantages and Disadvantages
Table 35: NanO2 (DDFPe): Clinical Trials, 2023
Table 36: Sanguinate: Raw Material and Method Overview
Table 37: Sanguinate: Advantages and Disadvantages
Table 38: Sanguinate: Clinical Trials, 2023
Table 39: Vidaphor: Raw Material and Method Overview
Table 40: Vidaphor: Advantages and Disadvantages
Table 41: Vidaphor: Clinical Trials, 2023

Summary Figure: Global Market for Artificial Blood, 2020-2028
Figure 1: The Blood Continuum
Figure 2: Medical Use of Human Red Blood Cells in the U.S., 2019
Figure 3: Estimated Number of New Cancer Cases from 2020 to 2040
Figure 4: Discards of Blood Donations, by Reason, 2018
Figure 5: Artificial Blood Manufactured from Different Sources
Figure 6: History of HBOCs Developed Using Recombinant Technology
Figure 7: Classification of Modified Hemoglobin Solution Based on Methods
Figure 8: Classification of Different Types of Oxygen Carriers
Figure 9: Generations of Perfluorocarbon Emulsions
Figure 10: Advantages and Disadvantages of PFC Emulsions
Figure 11: Evolution of HBOCs
Figure 12: Advantages and Disadvantages of HBOCs
Figure 13: Global Potential Market for Artificial Blood, by Application, 2028
Figure 14: Biosynthetic RBC vs Artificial Blood Substitutes
Figure 15: Artificial Blood: Parameters for Product Analysis
Figure 16: Hemopure: Product Analysis
Figure 17: HemO2life: Product Analysis
Figure 18: NanO2 (DDFPe): Product Analysis
Figure 19: Sanguinate: Product Analysis
Figure 20: Current Competition in the Global Artificial Blood Market